CELLINK Q5 2020 Results and MatTek Acquisition

A Acquisition of Ginolis - main synergies Enabling the next generation of bioprinting systems The increased demand for microfluidic and lateral flow IVD tests, PoC-tests Synergies with the Group's existing product offering and future product development Increased capacity to deliver larger automation workflows CELLINK LIFE SCIENCES O CELLINK 2021, All rights reserved.

View entire presentation